{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:25:13Z","timestamp":1794565513320,"version":"4.9.1"},"reference-count":66,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jpet.2026.104951","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:10:15Z","timestamp":1779289815000},"page":"104951","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chimeric antigen receptor T-cell therapy in rheumatoid arthritis"],"prefix":"10.1016","volume":"393","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8514-3259","authenticated-orcid":false,"given":"Pawe\u0142","family":"Dec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1320-9890","authenticated-orcid":false,"given":"Adam","family":"Kubisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6821-0086","authenticated-orcid":false,"given":"Paulina","family":"Plewa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Pawlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10416","key":"10.1016\/j.jpet.2026.104951_bib1","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jpet.2026.104951_bib2","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1016\/S2665-9913(24)00240-6","article-title":"Barriers to CAR T-cell therapy in rheumatology","volume":"7","author":"Lungova","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jpet.2026.104951_bib3","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41422-024-01068-2","article-title":"Fourth-generation chimeric antigen receptor T-cell therapy is tolerable and efficacious in treatment-resistant rheumatoid arthritis","volume":"35","author":"Li","year":"2025","journal-title":"Cell Res"},{"key":"10.1016\/j.jpet.2026.104951_bib4","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/intimm\/dxab011","article-title":"IL-6: from arthritis to CAR-T-cell therapy and COVID-19","volume":"33","author":"Kishimoto","year":"2021","journal-title":"Int Immunol"},{"issue":"3","key":"10.1016\/j.jpet.2026.104951_bib5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jpet.2026.104951_bib6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.coi.2021.02.010","article-title":"Mechanisms of response and resistance to CAR T cell therapies","volume":"69","author":"Berger","year":"2021","journal-title":"Curr Opin Immunol"},{"issue":"6","key":"10.1016\/j.jpet.2026.104951_bib7","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jpet.2026.104951_bib8","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3389\/fonc.2019.01237","article-title":"Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies","volume":"9","author":"Cheng","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.jpet.2026.104951_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1113882","article-title":"The current landscape of CAR T-cell therapy for solid tumors: mechanisms, research progress, challenges, and counterstrategies","volume":"14","author":"Daei Sorkhabi","year":"2023","journal-title":"Front Immunol"},{"issue":"19","key":"10.1016\/j.jpet.2026.104951_bib10","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.3390\/jcm12196124","article-title":"Exploring CAR-T cell therapy side effects: mechanisms and management strategies","volume":"12","author":"Zhang","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.jpet.2026.104951_bib11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.semcancer.2019.12.002","article-title":"Mechanisms of resistance to CAR T cell therapies","volume":"65","author":"Singh","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.jpet.2026.104951_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152479","article-title":"Advancing autoimmune rheumatic disease treatment: CAR-T cell therapies \u2013 evidence, safety, and future directions","volume":"67","author":"Ohno","year":"2024","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.jpet.2026.104951_bib13","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/ard-2024-226437","article-title":"CD-19 CAR-T cells for polyrefractory rheumatoid arthritis","volume":"84","author":"Lidar","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.jpet.2026.104951_bib14","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/s41409-023-02084-3","article-title":"Two for one? CAR-T therapy for lymphoma benefits concurrent autoimmune disorders","volume":"58","author":"Bachanova","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jpet.2026.104951_bib15","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"10.1016\/j.jpet.2026.104951_bib16","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2020-217844","article-title":"In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells","volume":"80","author":"Zhang","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.jpet.2026.104951_bib17","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.tips.2024.07.005","article-title":"Frontiers in CAR-T cell therapy for autoimmune diseases","volume":"45","author":"Li","year":"2024","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.jpet.2026.104951_bib18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4049\/jimmunol.2100643","article-title":"CD8+ T cells expressing an HLA-DR1 chimeric antigen receptor target autoimmune CD4+ T cells in an antigen-specific manner and inhibit the development of autoimmune arthritis","volume":"208","author":"Whittington","year":"2022","journal-title":"J Immunol"},{"issue":"21","key":"10.1016\/j.jpet.2026.104951_bib19","article-title":"Therapeutic potential of lipid nanoparticle-encapsulated CD19-targeting mRNAs in lupus and rheumatoid arthritis","volume":"12","author":"Guo","year":"2025","journal-title":"Adv Sci (Weinh)"},{"issue":"8","key":"10.1016\/j.jpet.2026.104951_bib20","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1158\/1078-0432.CCR-22-1491","article-title":"Synthetic biology in the engineering of CAR-T and CAR-NK cell therapies: facts and hopes","volume":"29","author":"Clubb","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jpet.2026.104951_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010117","article-title":"CAR-NK as a rapidly developed and efficient immunotherapeutic strategy against cancer","volume":"15","author":"W\u0142odarczyk","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.jpet.2026.104951_bib22","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keag195","article-title":"A new therapeutic frontier: CD19-targeting CAR-T cell therapy in rheumatoid arthritis: a concise report","volume":"65","author":"Kremer","year":"2026","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.jpet.2026.104951_bib23","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: the promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jpet.2026.104951_bib24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"issue":"7643","key":"10.1016\/j.jpet.2026.104951_bib25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jpet.2026.104951_bib26","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"issue":"6382","key":"10.1016\/j.jpet.2026.104951_bib27","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.jpet.2026.104951_bib28","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3390\/biom10020263","article-title":"Recent advances in allogeneic CAR-T cells","volume":"10","author":"Kim","year":"2020","journal-title":"Biomolecules"},{"issue":"5","key":"10.1016\/j.jpet.2026.104951_bib29","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tips.2024.03.004","article-title":"Direct in vivo CAR T cell engineering","volume":"45","author":"Short","year":"2024","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.jpet.2026.104951_bib30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.tips.2025.11.001","article-title":"Autologous, allogeneic, in vivo CAR for autoimmune diseases","volume":"47","author":"Li","year":"2026","journal-title":"Trends Pharmacol Sci"},{"issue":"11","key":"10.1016\/j.jpet.2026.104951_bib31","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1136\/ard-2024-226017","article-title":"Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis","volume":"83","author":"Haghikia","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jpet.2026.104951_bib32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40259-024-00692-z","article-title":"For the Club for Innovative Immunotherapies in Immune-Mediated Inflammatory Diseases (C3I). CAR T-cell therapy for rheumatic diseases: what does the future hold?","volume":"39","author":"Avouac","year":"2025","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.jpet.2026.104951_bib33","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40364-026-00905-3","article-title":"T-cell-targeted fusogenic nanovesicles generate CAR-T cells in vivo for rheumatoid arthritis therapy","volume":"14","author":"Liang","year":"2026","journal-title":"Biomark Res"},{"issue":"1","key":"10.1016\/j.jpet.2026.104951_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2025-006417","article-title":"CAR-T cell therapy for treatment-refractory rheumatic autoimmune diseases: a systematic review of clinical outcomes and safety profiles","volume":"12","author":"Santosa","year":"2026","journal-title":"RMD Open"},{"issue":"6","key":"10.1016\/j.jpet.2026.104951_bib35","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/ard-2024-225638","article-title":"Potential and pitfalls of repurposing the CAR-T cell regimen for the treatment of autoimmune disease","volume":"83","author":"Daamen","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.jpet.2026.104951_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.1091","article-title":"Cell-based therapies for the treatment of rheumatoid arthritis","volume":"11","author":"Moghaddam","year":"2023","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.jpet.2026.104951_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1334281","article-title":"Current status of immunological therapies for rheumatoid arthritis with a focus on antigen-specific therapeutic vaccines","volume":"15","author":"Zimmerman","year":"2024","journal-title":"Front Immunol"},{"issue":"15","key":"10.1016\/j.jpet.2026.104951_bib38","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.3390\/cells13151282","article-title":"Cell-based therapy and genome editing as emerging therapeutic approaches to treat rheumatoid arthritis","volume":"13","author":"Chasov","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.jpet.2026.104951_bib39","author":"de Vries"},{"issue":"11","key":"10.1016\/j.jpet.2026.104951_bib40","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","article-title":"An inducible caspase 9 safety switch for T-cell therapy","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jpet.2026.104951_bib41","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1126\/science.7694365","article-title":"Controlling signal transduction with synthetic ligands","volume":"262","author":"Spencer","year":"1993","journal-title":"Science"},{"issue":"5319","key":"10.1016\/j.jpet.2026.104951_bib42","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1126\/science.276.5319.1719","article-title":"HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia","volume":"276","author":"Bonini","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.jpet.2026.104951_bib43","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit Care Med"},{"issue":"3","key":"10.1016\/j.jpet.2026.104951_bib44","article-title":"Rheumatoid arthritis: pathogenesis and therapeutic advances","volume":"5","author":"Gao","year":"2024","journal-title":"MedComm (2020)"},{"key":"10.1016\/j.jpet.2026.104951_bib45","article-title":"Highlights of strategies targeting fibroblasts for novel therapies for rheumatoid arthritis","volume":"9","author":"Chu","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jpet.2026.104951_bib46","series-title":"Resistance to Anti-CD20 Antibodies and Approaches for Their Reversal","first-page":"273","article-title":"Clinical efficacy of anti-CD20 antibodies in autoimmune diseases","author":"Zian","year":"2024"},{"issue":"10","key":"10.1016\/j.jpet.2026.104951_bib47","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nrrheum.2009.184","article-title":"CD19: a promising B cell target for rheumatoid arthritis","volume":"5","author":"Tedder","year":"2009","journal-title":"Nat Rev Rheumatol"},{"issue":"13","key":"10.1016\/j.jpet.2026.104951_bib48","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.166137","article-title":"A nondepleting anti-CD19 antibody impairs B cell function and inhibits autoimmune diseases","volume":"8","author":"Boyles","year":"2023","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.jpet.2026.104951_bib49","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3390\/ijms23020905","article-title":"Rheumatoid arthritis: pathogenic roles of diverse immune cells","volume":"23","author":"Jang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jpet.2026.104951_bib50","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13075-024-03343-4","article-title":"Targeting pathogenic fibroblast-like synoviocyte subsets in rheumatoid arthritis","volume":"26","author":"Qian","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jpet.2026.104951_bib51","doi-asserted-by":"crossref","DOI":"10.37349\/ei.2025.1003185","article-title":"A new therapeutic pathway in autoimmune diseases: chimeric antigen receptor T cells (CAR-T) targeting specific cell subtypes or antigen-specific B lymphocytes\u2014a brief review","volume":"5","author":"Segovia","year":"2025","journal-title":"Explor Immunol"},{"issue":"5","key":"10.1016\/j.jpet.2026.104951_bib52","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1093\/rheumatology\/keae714","article-title":"Remission of lymphoma and rheumatoid arthritis following anti-CD19 chimeric antigen receptor T-cell therapy for diffuse large B-cell lymphoma","volume":"64","author":"Masihuddin","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.jpet.2026.104951_bib53","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1182\/blood.2024024523","article-title":"In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand","volume":"144","author":"Nicolai","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jpet.2026.104951_bib54","doi-asserted-by":"crossref","first-page":"7733","DOI":"10.1182\/blood-2024-208743","article-title":"Impact of autoimmune disease on toxicity and outcomes after axicabtagene ciloleucel in patients with diffuse large B cell lymphoma","volume":"144","author":"Shamis","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jpet.2026.104951_bib55","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002907","article-title":"CAR T cells for treating autoimmune diseases","volume":"9","author":"Blache","year":"2023","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.jpet.2026.104951_bib56","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s12016-025-09113-7","article-title":"CAR T cell therapy for rheumatoid arthritis","volume":"68","author":"Freeley","year":"2025","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jpet.2026.104951_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1399802","article-title":"Bi-specific T-cell engagers (BiTEs) in prostate cancer and strategies to enhance development: hope for a BiTE-r future","volume":"15","author":"Lampe","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jpet.2026.104951_bib58","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/bs.ircmb.2022.05.001","article-title":"Opportunities and challenges of bi-specific antibodies","volume":"369","author":"Segu\u00e9s","year":"2022","journal-title":"Int Rev Cell Mol Biol"},{"key":"10.1016\/j.jpet.2026.104951_bib59","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1136\/annrheumdis-2024-eular.2735","article-title":"POS0464 serum proteomic analysis identifies markers associated with anti-CD19 CAR T therapeutic response in autoimmune diseases","volume":"83","author":"Chou","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpet.2026.104951_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1537054","article-title":"Editorial: single-domain antibodies-biology, engineering and emerging applications, volume II","volume":"15","author":"Henry","year":"2024","journal-title":"Front Immunol"},{"issue":"14","key":"10.1016\/j.jpet.2026.104951_bib61","doi-asserted-by":"crossref","first-page":"7743","DOI":"10.3390\/ijms25147743","article-title":"Advancements in personalized CAR-T therapy: comprehensive overview of biomarkers and therapeutic targets in hematological malignancies","volume":"25","author":"Olejarz","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.jpet.2026.104951_bib62","doi-asserted-by":"crossref","first-page":"70","DOI":"10.21103\/Article12(1)_GE","article-title":"Role of biomolecules and biologics in precision medicine, personalized medicine, and emerging therapies","volume":"12","author":"Rao","year":"2022","journal-title":"Int J Biomed"},{"key":"10.1016\/j.jpet.2026.104951_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100702","article-title":"New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma","volume":"51","author":"Dal Bo","year":"2020","journal-title":"Drug Resist Updat"},{"issue":"6460","key":"10.1016\/j.jpet.2026.104951_bib64","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1126\/science.aax4588","article-title":"Translational genomics and precision medicine: moving from the lab to the clinic","volume":"365","author":"Zeggini","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.jpet.2026.104951_bib65","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1055\/s-0043-1777752","article-title":"Reshaping neuroimmunology: diagnosis and treatment in the era of precision medicine","volume":"81","author":"Dos Passos","year":"2023","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.jpet.2026.104951_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.923419","article-title":"Novel treatments for pediatric relapsed or refractory acute B-cell lineage lymphoblastic leukemia: precision medicine era","volume":"10","author":"Mengxuan","year":"2022","journal-title":"Front Pediatr"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652601150X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652601150X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:48:34Z","timestamp":1794563314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652601150X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":66,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S002235652601150X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104951","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric antigen receptor T-cell therapy in rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104951","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104951"}}